Evaluation of corneal intrastromal voriconazole injection as an adjuvant approach in recalcitrant fungal keratitis.

IF 2 Q1 OPHTHALMOLOGY
Khaled El Ghonemy Said, Nada Mohammed Aggour, Ahmed Ibrahim Basiony
{"title":"Evaluation of corneal intrastromal voriconazole injection as an adjuvant approach in recalcitrant fungal keratitis.","authors":"Khaled El Ghonemy Said, Nada Mohammed Aggour, Ahmed Ibrahim Basiony","doi":"10.1186/s12348-026-00599-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fungal keratitis is a sight-threatening condition that accounts for approximately 30-40% of keratitis cases in developing countries. Its management remains challenging despite the availability of various antifungal agents, highlighting the potential role of targeted drug delivery in recalcitrant cases.</p><p><strong>Purpose: </strong>To evaluate the efficacy of corneal intrastromal voriconazole (ISV) injection in the management of fungal keratitis unresponsive to conventional antifungal therapy.</p><p><strong>Methods: </strong>This prospective interventional case series included 21 eyes of 21 patients with smear-positive fungal keratitis that failed to respond to at least two weeks of topical antifungal therapy. All patients underwent detailed ophthalmological examination and ulcer assessment using anterior segment optical coherence tomography (AS-OCT). Intrastromal voriconazole (50 µg/0.1 mL) was administered circumferentially around the ulcer. Treatment response was evaluated through serial follow-up, including assessment of ulcer size, infiltrate extent, hypopyon level, presence of satellite lesions, and best-corrected visual acuity (BCVA).</p><p><strong>Results: </strong>The mean age of the patients was 57.19 ± 6.74 years, with a predominance of males (76.2%). Most patients were from rural areas (76.2%) and had a history of vegetative trauma (71.4%). The mean ulcer size was 4.64 ± 0.95 mm, and the mean infiltrate size was 6.43 ± 1.29 mm. Hypopyon was present in 57.1% of cases, and the mean ulcer depth measured by AS-OCT was 257.14 ± 68.12 μm. Aspergillus was the most isolated organism (52.4%). BCVA improved significantly from 2.71 ± 0.46 LogMAR at baseline to 1.34 ± 0.68 at 3 months (P < 0.001). Complete resolution was achieved in 19 patients (90.5%). Fourteen patients (66.7%) responded to a single injection, while five (23.8%) and two (9.5%) required two and three injections, respectively. Most cases (84.2%) resolved within 2-4 weeks. Two patients (9.5%) showed disease progression and required therapeutic penetrating keratoplasty and were excluded from the final analysis.</p><p><strong>Conclusion: </strong>Intrastromal voriconazole injection appears to be an effective adjunctive treatment for recalcitrant fungal keratitis, improving clinical outcomes and potentially reducing the need for therapeutic or tectonic keratoplasty.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294420/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-026-00599-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Fungal keratitis is a sight-threatening condition that accounts for approximately 30-40% of keratitis cases in developing countries. Its management remains challenging despite the availability of various antifungal agents, highlighting the potential role of targeted drug delivery in recalcitrant cases.

Purpose: To evaluate the efficacy of corneal intrastromal voriconazole (ISV) injection in the management of fungal keratitis unresponsive to conventional antifungal therapy.

Methods: This prospective interventional case series included 21 eyes of 21 patients with smear-positive fungal keratitis that failed to respond to at least two weeks of topical antifungal therapy. All patients underwent detailed ophthalmological examination and ulcer assessment using anterior segment optical coherence tomography (AS-OCT). Intrastromal voriconazole (50 µg/0.1 mL) was administered circumferentially around the ulcer. Treatment response was evaluated through serial follow-up, including assessment of ulcer size, infiltrate extent, hypopyon level, presence of satellite lesions, and best-corrected visual acuity (BCVA).

Results: The mean age of the patients was 57.19 ± 6.74 years, with a predominance of males (76.2%). Most patients were from rural areas (76.2%) and had a history of vegetative trauma (71.4%). The mean ulcer size was 4.64 ± 0.95 mm, and the mean infiltrate size was 6.43 ± 1.29 mm. Hypopyon was present in 57.1% of cases, and the mean ulcer depth measured by AS-OCT was 257.14 ± 68.12 μm. Aspergillus was the most isolated organism (52.4%). BCVA improved significantly from 2.71 ± 0.46 LogMAR at baseline to 1.34 ± 0.68 at 3 months (P < 0.001). Complete resolution was achieved in 19 patients (90.5%). Fourteen patients (66.7%) responded to a single injection, while five (23.8%) and two (9.5%) required two and three injections, respectively. Most cases (84.2%) resolved within 2-4 weeks. Two patients (9.5%) showed disease progression and required therapeutic penetrating keratoplasty and were excluded from the final analysis.

Conclusion: Intrastromal voriconazole injection appears to be an effective adjunctive treatment for recalcitrant fungal keratitis, improving clinical outcomes and potentially reducing the need for therapeutic or tectonic keratoplasty.

角膜基质内伏立康唑佐剂治疗顽固性真菌性角膜炎的疗效评价。
背景:真菌性角膜炎是一种威胁视力的疾病,约占发展中国家角膜炎病例的30-40%。尽管有各种抗真菌药物可用,但其管理仍然具有挑战性,突出了靶向药物递送在顽固性病例中的潜在作用。目的:评价角膜层内伏立康唑(ISV)注射液治疗常规抗真菌治疗无效的真菌性角膜炎的疗效。方法:该前瞻性介入病例系列包括21例涂片阳性真菌性角膜炎患者的21只眼睛,这些患者对至少两周的局部抗真菌治疗无效。所有患者都接受了详细的眼科检查和溃疡评估,使用前段光学相干断层扫描(AS-OCT)。在溃疡周围周向胃内注射伏立康唑(50µg/0.1 mL)。通过一系列随访评估治疗效果,包括评估溃疡大小、浸润程度、hypohypion水平、卫星病变的存在和最佳矫正视力(BCVA)。结果:患者平均年龄57.19±6.74岁,男性居多(76.2%)。大多数患者来自农村(76.2%),有植物性创伤史(71.4%)。溃疡平均大小为4.64±0.95 mm,浸润平均大小为6.43±1.29 mm。57.1%的病例存在溃疡,AS-OCT测得的平均溃疡深度为257.14±68.12 μm。曲霉是分离率最高的菌(52.4%)。BCVA从基线时的2.71±0.46 LogMAR显著改善至3个月时的1.34±0.68 LogMAR (P)结论:角膜基质内伏立康唑注射液似乎是难治性真菌性角膜炎的有效辅助治疗方法,可改善临床结果,并可能减少治疗性或构造性角膜移植术的需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
3.40%
发文量
39
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书